{'fraction_non_alphanumeric': 0.04300168634064081, 'fraction_numerical': 0.03204047217537943, 'mean_word_length': 4.818627450980392, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide].

OBJECTIVE
To determine the effect of rebamipide on the expression of Toll-like recepter 4 (TLR4) and TNF-alpha release in pulmonary epithelial cell line A549.


METHODS
Lipopolysaccharide (LPS) was used to induce A549 in vitro, which was divided into 4 groups: a control group, a model group(LPS), and 2 intervention groups (10 mg/L rebamipide plus LPS; 30 mg/L rebamipide plus LPS). TNF-alpha release was detected with ELISA and expression of TLR4 was detected with RT-PCR and Western blot.


RESULTS
A549 cells were stimulated with LPS and TNF-alpha release was increased compared with the control group (P<0.01), peaking at 6 h. Expression of TLR4 was also increased compared with the control group (P<0.01), but it was inhibited by rebamipide compared with the model group (P<0.05). There was no significant difference between the 2 intervention groups (P>0.05).


CONCLUSION
The antiinflammatory mechanism of rebamipide may be reducing cytokine release by inhibiting TLR4 expression. Rebamipide may be used as a supplementary anti-infection drug.